e-Drug3D

2151

LAZERTINIB

INN
LAZERTINIB

cas 1903008-80-9

CLASS

ANTINEOPLASTIC
EGFR KINASE INHIBITOR
TREATMENT OF ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)

ROUTE (list)

ORAL

ATC code

L01EB09

PK parameters

Tmax 3 HOUR
VD 2680 LITER
Cl 36.4 LITER / HOUR
PPB 99.2 PERCENT
t1/2 88.8 HOUR

Target

TARGET EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)

PDB
7UKV (WILD TYPE EGFR IN COMPLEX WITH LAZERTINIB (YH25448))

Download experimental 3D coordinates of ZRT with added hydrogens

Download SDF file

2-Propenamide, N-[5-[[4-[4-[(dimethylamino)methyl]-3-phenyl-1H-pyrazol-1-yl]-2-pyrimidinyl]amino]-4-methoxy-2-(4-morpholinyl)phenyl]- (ACI)

Formula:
C30H34N8O3

Calculated chemical properties:

MW 554.65
NB_atoms 41
XLogP 4.10
PSA 99.06
NB_HD 2
NB_HA 11
fsp3 0.27
Lipinski(0=no;1=yes) 0

FDA
NDA 219008 (label) INN (LAZERTINIB MESYLATE) LAZCLUZE (JANSSEN BIOTECH) APPROVAL= AP YEAR= 2024 NEWMOLECULARENTITY